Related Experiment Videos

Disparities in Paediatric Injury Mortality between Aboriginal and Non-Aboriginal Populations in British Columbia,

Ofer Amram1, Blake Byron Walker2, Nadine Schuurman3

  • 1Department of Geography, Simon Fraser University, 8888 University Drive, Burnaby, BC V5A 1S6, Canada. oamram@sfu.ca.

International Journal of Environmental Research and Public Health
|July 12, 2016
PubMed

Insights

Childhood injury deaths in Canada disproportionately affect Aboriginal youth. Targeted, community-specific prevention strategies are crucial, especially in high-risk regions, to address these significant disparities.

Area of Science:

  • Public Health
  • Epidemiology
  • Pediatric Injury Prevention

Background:

  • Injury is the primary cause of death for children and youth in Canada.
  • Known disparities exist in injury mortality rates between Aboriginal and non-Aboriginal populations.
  • Detailed understanding of age-, sex-, and mechanism-specific injury death patterns is lacking.

Purpose of the Study:

  • To examine paediatric mortality patterns in British Columbia from 2001 to 2009.
  • To identify disparities in injury mortality between Aboriginal and non-Aboriginal children.
  • To analyze age- and mechanism-specific injury deaths using the Preventable Years of Life Lost (PrYLL) metric.

Main Methods:

  • Utilized comprehensive vital statistics registry data for British Columbia (2001-2009).
  • Calculated age-adjusted mortality rates and odds ratios (OR) to compare Aboriginal and non-Aboriginal children.
  • Applied the Preventable Years of Life Lost (PrYLL) metric to assess injury mechanisms and age-group differences.

Main Results:

  • A significantly higher age-adjusted mortality rate was observed in Aboriginal children (OR = 2.08).
  • Specific age groups showed higher death rates from assault, suffocation, and fire among Aboriginal children.
  • Regional disparities in PrYLL were mapped, potentially correlating with rural/remote areas and higher Aboriginal populations.

Conclusions:

  • Significant disparities in paediatric injury mortality persist between Aboriginal and non-Aboriginal children in British Columbia.
  • Understanding specific injury mechanisms and age patterns is vital for effective prevention.
  • Community-specific injury prevention policies are urgently needed, particularly in regions with high PrYLL, to address these disparities.

Keywords:
Aboriginal populationinjury mortalitypaediatric injury

Related Concept Videos

Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
190
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
167
Drug Dosing: Infants and Children01:29

Drug Dosing: Infants and Children

Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
172
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
126
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
147